Pelvic Floor Dysfunction is a series of chronic diseases caused by the damage or dysfunction of the pelvic floor muscles, ligaments, and fascia, with a global incidence of over 30% in adult women, and up to 40%–50% in postmenopausal women and multiparous women.
Core types include stress urinary incontinence (SUI), pelvic organ prolapse (POP, including uterine prolapse, cystocele, rectocele, and vaginal vault prolapse), female sexual dysfunction, and chronic pelvic pain. The main causes include pregnancy and vaginal delivery, aging, menopause, obesity, long-term increased abdominal pressure, and pelvic surgery history. The disease does not threaten life, but seriously affects women's quality of life, social activities, and mental health, and is known as the "social cancer".
China has the largest annual number of pelvic floor reconstructive surgery cases in the world (over 200,000 cases annually). The success rate of TVT-O surgery for stress urinary incontinence exceeds 95%, and the success rate of laparoscopic sacrocolpopexy for pelvic organ prolapse exceeds 90%, on par with top European and American centers. The recurrence rate of surgery is less than 10% within 5 years, lower than the global average.
The popularity rate of minimally invasive pelvic floor surgery in top Chinese centers exceeds 95%, with laparoscopic and robot-assisted surgery as the mainstream. The surgical trauma is small, the hospital stay is short (3–5 days), and the recovery is fast, which significantly reduces the risk of complications compared with traditional open surgery.
China's original "pelvic floor rehabilitation + integrated traditional Chinese and Western medicine" conservative treatment protocol has an effective rate of over 80% for mild to moderate PFD, avoiding surgery for most patients. Acupuncture and biofeedback combined therapy for stress urinary incontinence has an effective rate of over 85%, a unique advantage of Chinese treatment.
Top centers have rich experience in the treatment of recurrent PFD, complex pelvic organ prolapse, and combined urinary and bowel dysfunction, with MDT teams including gynecology, urology, anorectal surgery, and rehabilitation medicine to formulate personalized treatment plans, significantly improving the success rate of complex cases.
The cost of TVT-O surgery for stress urinary incontinence in top Chinese centers is only 3,000–5,000 USD, and the cost of laparoscopic sacrocolpopexy for pelvic organ prolapse is only 8,000–12,000 USD, which is 1/4–1/3 of that in the US. Surgery can be arranged within 1–2 weeks, while the waiting period in Europe and America is often 3–6 months.